Sorafenib in the treatment of AML patients with FLT3-ITD mutation: a cohort study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-14004731

Enrollment

Unknown

Registered

2014-05-09

Start date

2014-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

Induction Group:Sorafenib

Consolidation Group:Sorafenib

Maintenance Group:Sorafenib

Salvage Group:Sorafenib

Alleviative Group:Sorafenib

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Defenitely diagnosed as acute myeloid leukemia; 2. FLT3-ITD mutation positive is confirmed; 3. Accept the prescription of sorafenib.

Exclusion criteria

Exclusion criteria: 1. Can not tolerate oral administration; 2. Refuse to follow the sorafenib prescription; 3. Other reasons that reserchers consider as contra-indication of this study.

Design outcomes

Primary

Measure	Time frame
CR;Survival;LFS;	—

Contacts

Public ContactDepei WU

Department of Hematology, the First Affiliated Hospital of Soochow University

lcsy2013@sina.com+86 0512 67781856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026